8-K 1 cytori_8k080514.htm CYTORI THERAPEUTICS FORM 8-K cytori_8k080514.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 5, 2014

CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-34375
33-0827593
(State or other jurisdiction of incorporation)
(Commission File
Number)
(I.R.S. Employer Identification No.)

3020 Callan Road, San Diego, California 92121
(Address of principal executive offices) (Zip Code)

(858) 458-0900
(Registrant's telephone number, including area code)

n/a
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

 
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 

 
 
 
Item 8.01 Other Events.
 
On August 5, 2014, Cytori Therapeutics, Inc.  (“Cytori”) issued the attached press release providing an update on the status of the ATHENA trial.
 

 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
     


Exhibit No.     
Description
99.1
Cytori Therapeutics, Inc. Press Release, dated August 5, 2014
 


 
 
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 CYTORI THERAPEUTICS, INC.
   
 Date:  August 5, 2014
 By:  
/s/ Marc H. Hedrick
 
               Marc H. Hedrick
 
               President, Chief Executive Officer



 
 
 

EXHIBIT INDEX
     
 
Exhibit
No.
 
  
 
Description
 
   
   
99.1
  
Cytori Therapeutics, Inc. Press Release, dated August 5, 2014